Somatostatin receptor in neuroendocrine tumours
1 EU-approved indication in neuroendocrine tumours needs a Somatostatin receptor result: lutetium (177Lu) oxodotreotide (advanced).
Site
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Somatostatin receptor-positive1 | ||||
Lutathera | Monotherapy | Any line advanced | Gastroenteropancreatic NET only; Progressive; well-differentiated (G1 and G2) | |
5 approvals for NET need no biomarker and apply whatever the result. All approvals for NET
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Lutetium (177Lu) oxodotreotide (Lutathera)
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.